Notizie
SOM Biotech completa il processo di reclutamento nello studio di Fase IIb sul trattamento della corea nella malattia di Huntington
SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligence platform (SOMAIPRO®), is pleased to announce that the recruitment of the Phase IIb clinical study with SOM3355 as a treatment for Huntington’s chorea has Leggi tutto...